Bank of Montreal’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-125
Closed -$51K 4420
2021
Q1
$51K Sell
125
-2,352
-95% -$1.08M ﹤0.01% 3687
2020
Q4
$1.33M Sell
2,477
-208
-8% -$122K ﹤0.01% 2052
2020
Q3
$1.51M Sell
2,685
-7,213
-73% -$2.4M ﹤0.01% 1785
2020
Q2
$1.09M Buy
9,898
+581
+6% +$51K ﹤0.01% 1887
2020
Q1
$589K Buy
9,317
+9,087
+3,951% +$609K ﹤0.01% 1905
2019
Q4
$16K Buy
230
+70
+44% +$5.19K ﹤0.01% 4412
2019
Q3
$13K Buy
160
+74
+86% +$4.89K ﹤0.01% 4323
2019
Q2
$6K Buy
+86
New +$8.16K ﹤0.01% 4645
2019
Q1
Sell
-14
Closed -$1K 4568
2018
Q4
$1K Buy
14
+7
+100% +$980 ﹤0.01% 4541
2018
Q3
$1K Sell
7
-242
-97% -$39.2K ﹤0.01% 4561
2018
Q2
$43K Buy
249
+8
+3% +$1.31K ﹤0.01% 3476
2018
Q1
$35K Hold
241
﹤0.01% 3370
2017
Q4
$49K Sell
241
-858
-78% -$176K ﹤0.01% 3265
2017
Q3
$353K Buy
1,099
+142
+15% +$38.8K ﹤0.01% 2430
2017
Q2
$216K Hold
957
﹤0.01% 2621
2017
Q1
$216K Buy
957
+226
+31% +$45.9K ﹤0.01% 2429
2016
Q4
$146K Buy
731
+716
+4,773% +$156K ﹤0.01% 2649
2016
Q3
$4K Buy
+15
New +$5.26K ﹤0.01% 3761

Other funds holding MCRB

Bank of Montreal's MCRB Position: Q2 2021 in Review

Bank of Montreal sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 125 shares — an estimated $51K sold.

Bank of Montreal first reported a position in MCRB in Q3 2016 and held it in 18 quarters. The position peaked at $1.51M in Q3 2020. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • Bank of Montreal reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 125 Seres Therapeutics shares in Q2 2021, an estimated $51K.
  • Bank of Montreal first reported a position in Seres Therapeutics in Q3 2016 and held it in 18 quarters.
  • Bank of Montreal's Seres Therapeutics position peaked at $1.51M in Q3 2020.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.